NovoCure

NVCR

Market cap $1.53B

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.

NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago.

NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada's Drug Agency's assessment and reimbursement recommendation for TTFields therapy in glioblastoma. “Glioblastoma is one of the most aggressive cancers, and treatment options.

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.

NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase 2 PANOVA-4 trial in 1st-line metastatic pancreatic cancer; topline data is expected in Q1 2026. Full-year 2025 revenues grew 8% year-over-year to $655.4 million, supported by 4,620 active TTFields patients globally and strong U.S. sales momentum.

Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.

NovoCure stock (NVCR) is up over 30% following the FDA's approval of its Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment in almost 30 years.